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Abstract
Objective: Myoclonus-dystonia (M-D) is a hyperkinetic movement disorder,
typically alcohol-responsive upper body myoclonus and dystonia. The majority
of autosomal dominant familial cases are caused by epsilon-sarcoglycan gene
(SGCE) mutations. Previous publications have observed increased rates of psy-
chiatric disorders amongst SGCE mutation-positive populations. We analyzed
the psychiatric data from four international centers, forming the largest cohort
to date, to further determine the extent and type of psychiatric disorders in M-
D. Methods: Psychiatric data from SGCE mutation-positive M-D cohorts, col-
lected by movement disorder specialists in the Netherlands, United Kingdom,
United States, and Germany, were analyzed. These data were collected using
standardized, systematic questionnaires allowing classification of symptoms
according to Diagnostic and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV) criteria. Based on motor findings and SGCE mutation analysis,
participants were classified into one of three groups: manifesting carriers, non-
manifesting carriers and noncarriers. Results: Data from 307 participants were
evaluated (140 males, 167 females, mean age at examination: 42.5 years). Two-
thirds of motor affected mutation carriers (n = 132) had ≥1 psychiatric diagno-
sis, specific, and social phobias being most common followed by alcohol depen-
dence and obsessive-compulsive disorder (OCD). Compared to familial
controls, affected mutation carriers had significantly elevated overall rates of
psychiatric disorders (P < 0.001). The most significant differences were
observed with alcohol dependence (P < 0.001), OCD (P < 0.001), social and
specific phobias (P < 0.001). Interpretation: M-D due to SGCE mutations is
associated with specific psychiatric disorders, most commonly OCD, anxiety-
related disorders, and alcohol dependence. These suggest either a potential
pleiotropic function for SGCE within the central nervous system or a secondary
effect of the motor disorder.
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Introduction
Myoclonus-dystonia (M-D) is a rare hyperkinetic move-
ment disorder typically characterized by myoclonus of the
trunk and upper limbs in conjunction with dystonia of
the neck or hands (writer’s cramp).1,2 Onset of motor
symptoms is usually in the first two decades of life and
are typically alcohol responsive. A proportion of M-D
cases are caused by mutations in the epsilon-sarcoglycan
gene (SGCE), which encodes the epsilon-sarcoglycan pro-
tein.3 More than 40 different point mutations have now
been identified, these resulting in proteosomal degrada-
tion and failure of expression of the mutated protein at
the cell-surface membrane.4
Psychiatric symptoms have been reported to be prevalent
amongst SGCEmutation-positive cases.5,6 Depression, anxi-
ety disorders and obsessive-compulsive disorder (OCD)7–9
have been frequently and repeatedly reported whereas other
psychiatric diagnoses, for example, psychosis,10 schizophre-
nia,7 schizoaffective disorder,11 Attention Deficit Hyperac-
tivity Disorder (ADHD)12, and Anorexia Nervosa13 have
been described predominantly in single case reports. More
recently, larger cohort studies have used systematic and
standardized methods to compare results from SGCE muta-
tion-positive M-D cohorts to control groups, finding OCD,
in particular compulsivity,7 and anxiety-related disorders to
be the most prominent reported neuropsychiatric features.8
This study combines previously collected standardized
data from four international centers (Netherlands, United
Kingdom, United States, and Germany; see Table 1 for an
overview of the clinical centers involved) to form the lar-
gest single collection of psychiatric data from SGCE
mutation carriers. Given the increasing recognition of
nonmotor symptoms as a comorbid feature of dystonic
disorders, this large cohort allows further assessment of
the type and frequency of psychiatric symptoms in M-D
populations as well as another opportunity to examine
whether these symptoms represent a pleiotropic function
for the epsilon-sarcoglycan protein or a secondary conse-
quence of the motor disorder.
Methods
Movement disorder research groups that had previously
published standardized and systematic psychiatric data
from SGCE mutation-positive M-D cohorts were con-
tacted and asked to provide a summary of their findings
for each case. Each center was also asked to provide data
from any as yet unpublished cases that could be included
in analysis (Table 1; Fig. 1).
Standard protocol approvals, registrations
and patient consents
Ethical approval for data collection was obtained from
the respective research and ethics committees in each of
the recruiting countries (Netherlands, United Kingdom,
United States and Germany). Written informed consent
or assent was obtained from each participant or their par-
ent/guardian prior to involvement in the study.
Table 1. Demographic features of the study population.
Demographics MC (n = 132) NMC (n = 38) NC (n = 137) Total (n = 307)
Gender
Male (%) 70 (53) 22 (58) 48 (35) 140 (46)
Female (%) 62 (47) 16 (42) 89 (65) 167 (54)
Mean age at examination (SD) 40.5 years (17.0 years) 50.4 years (17.1 years) 41.2 years (14.0 years) 42.1 years (16.1 years)
Age at onset of motor symptoms (n %)
<18 years 65 (49) – – 65 (21)
18–30 years 4 (3) – – 4 (1.3)
30–40 years 1 (0.8) – – 1 (0.3)
40–50 years 1 (0.8) – – 1 (0.3)
Unknown 68 (52) – – 68 (22)
Number of cases per center (%)
Academic Medical Centre,
Amsterdam, the Netherlands8,14
31 (23) 9 (24) 33 (24) 73 (24)
Beth Israel Medical Centre,
New York, U.S.A.9,15
20 (15) 9 (24) 33 (24) 62 (20)
University of Tubingen,
Tubingen, Germany
54 (41) 10 (26) 55 (40) 119 (39)
Cardiff University, Cardiff,
United Kingdom7
27 (20) 10 (26) 16 (12) 53 (17)
MC, manifesting carriers; NMC, nonmanifesting carriers; NC, noncarrier; SD, standard deviation.
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Genetic analysis
As reported previously, DNA from all samples was
analyzed by direct sequencing and Multiplex ligation-
dependent probe amplification (MLPA) of SGCE
exons 1–12.7–9,14,15
Clinical assessment
All cases underwent a neurological examination by a
movement disorders expert at their original medical cen-
ter and were classified according to their motor and
genetic status into three groups: (1) manifesting carriers
(MC): SGCE mutation and movement disorder
(n = 132), (2) nonmanifesting carriers (NMC): SGCE
mutation and no movement disorder (n = 38) and (3)
noncarriers (NC): no SGCE mutation and no movement
disorder (n = 137) (Table 1).
Psychiatric assessment
All centers used standardized assessment tools to establish
lifetime psychiatric diagnoses according to the Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(DSM-IV) criteria in their patient population. These
included the Structured Clinical Interview (SCID-I)16
(Netherlands), MINI International Neuropsychiatric
Interview (M.I.N.I.)17 (Netherlands and United Kingdom)
and Composite International Diagnostic Interview
(CIDI)18 (United States and Germany) (Fig. 1). These
included the sections on major affective disorder (MAD),
generalized anxiety disorder (GAD), OCD, alcohol depen-
dence, panic disorder, social phobia and specific phobia.
Panic disorder, social phobia and specific phobia were
not assessed amongst participants recruited in the United
States and specific phobia was not assessed in those
recruited from the United Kingdom. These cases were
therefore excluded from the analysis of these disorders.
Data analysis and statistics
Overall and disorder specific rates of psychiatric diagnoses
were analyzed using chi-squared and Fisher’s exact testing
where appropriate. Stepwise logistic regression and multi-
level logistic regression were used to determine whether
additional variables (age at examination, gender, center,
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Figure 1. Diagrammatic representation of case recruitment from the four international centers. MC, manifesting carrier; NMC, nonmanifesting
carrier; NC, noncarrier; CIDI, Composite International Diagnostic Interview; M.I.N.I., MINI International Neuropsychiatric Interview; SCID-I,
Structured Clinical Interview.
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questionnaire type) impacted upon the presence of psy-
chiatric symptoms.
Results
Data from 307 cases (140 males and 167 females) with a
mean age at examination of 42.5 years (15.8 years) were
analyzed. Subdivided according to genetic and motor cri-
teria 132 MC, 38 NMC and 137 NC were included. There
was a near equal sex distribution in MC and NMC sub-
groups, unlike those with no mutation (NC) where
almost two-thirds of the cases were female. Mean age at
assessment was similar across MC and NC cohorts, while
those in the NMC sub-group were, on average, 10 years
older. Half of all MC cases had onset of their motor
symptoms at <18 years of age, although this data was
unknown in a similar number of cases (n = 68). Baseline
motor, psychiatric and genetic data from each of the
individual centers have been published previously, with
the exception of those recruited by the University of
Tubingen.7–9,14,15
Sixty five percent of MC cases met DSM-IV criteria
for ≥1 psychiatric disorder, with rates of all disorder
subtypes being above population estimates (Table 2).
Specific phobias (33%), social phobia (31%) and MADs
(30%) were the most common. Overall rates of psychi-
atric disorders were almost half that of population esti-
mates in both NMC (21%) and NC (27%) cohorts.
Symptoms consistent with MAD were the most com-
monly reported in both groups (NMC: 21%, NC: 27%)
while alcohol dependence was the least common with
no NMC cases and only 4 (3%) cases amongst nonmu-
tation carriers.
Comparison of the motor affected MC group with the
nonmutation carrying cohort (NC) found a significant
difference in the overall rate of psychiatric disorders
(OR 5.05, 95% confidence interval [CI] 2.91–8.80,
P < 0.001) as well as with each individual diagnosis.
Alcohol dependence (OR 10.64, 95% CI 3.44–36.72,
P < 0.001) and OCD (OR 7.11, 95% CI 2.50–16.52,
P < 0.001) demonstrated the largest differences. Social
and specific phobias were also significantly higher
amongst the MC cases (P < 0.001) (OR 6.30, 95% CI
2.50, 16.52 and OR 5.68, 95% CI 2.18, 15.44). In an
attempt to determine whether SGCE mutations had a
direct impact on psychiatric symptoms, NMC cases were
compared to both the NC controls and motor affected
(MC) cases. No significant difference was observed
between NMC and NC patients either overall or with
regard to individual diagnoses. However, comparison of
MC and NMC participants found a significant difference
in overall rates of psychiatric symptoms (OR 7.01, 95%
CI 2.79–18.20, P < 0.001) with the largest differences
again being seen with alcohol dependence, OCD and
social phobia, the latter two diagnoses being 10 and 12
times more likely, respectively, in the MC population. A
full summary of analyses can be seen in Table 3. Sensi-
tivity analyses using stepwise and multilevel logistic
regression found no significant effect of age at examina-
tion, gender, center or questionnaire type upon rate of
psychiatric symptoms.
Data relating to age at onset of both motor and psychi-
atric symptoms were available in 26 patients. Based on
recall, none reported onset of psychiatric symptomatology
prior to their comorbid motor features and the majority
reported that their motor symptoms had begun clearly in
advance of any subsequent psychiatric disorder. This was
most commonly seen in relation to alcohol dependence
(11/31). Twenty-two cases reported near simultaneous
onset of the motor symptoms and psychiatric symptoms,
with MAD (7/22) and social phobia (6/22) being the
most prevalent.












Any DSM-IV disorder 86 (65) 8 (21) 37 (27) 131 (43) 4820
Major affective disorder 40 (30) 6 (16) 20 (15) 66 (21) 17.120
Generalized anxiety disorder 23 (17) 1 (2.6) 10 (7) 34 (11) 5.120
Obsessive-compulsive disorder 28 (21) 1 (2.6) 5 (4) 34 (11) 421
Alcohol dependence 32 (24) 0 (0) 4 (3) 36 (12) 14.120
(n = 112) (n = 29) (n = 104) (n = 245)
Panic disorder 25 (22) 1 (3) 9 (9) 35 (14) 3.520
Social phobia 35 (31) 1 (3) 7 (7) 43 (18) 13.320
(n = 85) (n = 19) (n = 88) (n = 192)
Specific phobia 28 (33) 1 (5) 7 (8) 36 (19) 8.720
MC, manifesting carriers; NMC, non-manifesting carriers; NC, non-carrier; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth
edition.
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Discussion
This study represents the largest multicenter cohort of
SGCE mutation-positive M-D patients investigated using
systematic and standardized tools for psychiatric symp-
tomatology. Consistent with previous studies, we have
demonstrated an excess of psychiatric symptoms amongst
motor affected mutation carriers (MC) compared to
intrafamilial controls (NMC and NC), with alcohol
dependence, OCD, social and specific phobias demon-
strating the largest between group differences.7,9 Some of
the rarer psychiatric diagnoses, for example psychosis and
anorexia, were not identified in this cohort suggesting
that only a loose association exists between these rarer
disorders and SGCE mutations.
The overall rate of psychiatric disorders was almost one
and a half times greater in the MC (65%) cohort than
population estimates (48%). These latter values were
obtained from epidemiological studies in the United
States19 and New Zealand20 and considered to be from
comparable populations to our study cohort. Interest-
ingly, overall rates of psychiatric diagnoses in the NMC
(21%) and NC (27%) groups were only half that of the
population controls. There is no clear explanation for
this, although the relatively small group sizes, and an
awareness of the impact of psychiatric disorders (for
example alcohol excess in related MC family members)
may in part account for these findings.
Excess alcohol dependence amongst SGCE mutation
carriers has been consistently reported in previous stud-
ies.7,8,15 This was initially felt to be a secondary reactive
response to the therapeutic effect of alcohol on motor
symptoms.2,21 More recent studies have suggested that
SGCE may exert a gene independent effect in contributing
to these symptoms,6,7 potentially mirroring the mecha-
nisms involved in OCD and compulsivity, also prevalent
amongst this population.7 However, this study appears to
support the former view of a therapeutic response rather
than gene effect with a significant difference in alcohol
consumption between MC and NMC groups (P = 0.001)
compared to similar levels of intake in NMC and NC
patients (P = 0.29). Similarly, in those where age at onset
data for motor and psychiatric symptoms was available, a
third of those with primary motor symptoms reported
subsequent alcohol dependence (Table 4).
OCD was more prevalent amongst the MC group. As
OCD is not typically considered a secondary response to
a chronic, disabling disorder22 its relationship to M-D
and SGCE mutations continues to be of significant inter-
est. However, there remains some conflict in this area
with several previous publications reporting a strong
Table 3. Comparison of rates of psychiatric disorders between MC, NMC and NC cohorts.
Psychiatric diagnosis (DSM-IV) MC versus NC NMC versus NC MC versus NMC
Any DSM-IV disorder <0.001 (5.05; 2.91, 8.80) 0.46 (0.72; 0.28, 1.83) <0.001 (7.01; 2.79, 18.20)
Major affective disorder 0.002 (2.54; 1.34, 4.86) 0.86 (1.10; 0.36, 3.21) 0.10 (2.32; 0.84, 6.73)
Generalized anxiety disorder 0.011 (2.68; 1.15, 6.34) 0.29 (0.34; 0.02, 2.76) 0.02 (7.81; 1.06, 160.59)
Obsessive-compulsive disorder <0.001 (7.11; 2.50, 21.78) 0.76 (0.71; 0.03, 6.63) 0.007 (9.96; 1.37, 203.60)
Alcohol dependence <0.001 (10.64; 3.44, 36.72) 0.29 (0; 0, 5.65) 0.001 (1; 2.38, 1)
Panic disorder 0.006 (3.03; 1.26, 7.45) 0.35 (0.38; 0.02, 3.14) 0.02 (8.04; 1.07, 166.62)
Social phobia <0.001 (6.30; 2.50, 16.52) 0.51 (0.50; 0.02, 4.32) 0.002 (12.73; 1.73, 261.28)
Specific phobia <0.001 (5.68; 2.18, 15.44) 0.68 (0.64; 0.03, 5.85) 0.015 (8.84; 1.14, 186.62)
Results analyzed using chi-squared testing or Fisher’s exact testing where appropriate. Results expressed as: P-value (odds ratio, 95% confidence
interval). Statistically significant results (P < 0.05) are highlighted in bold. MC, manifesting carriers; NMC, non-manifesting carriers; NC, non-car-
rier; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
Table 4. Relationship between age at onset of motor and psychiatric






















Alcohol dependence 11 0 1
Panic disorder 4 0 1
Social phobia 2 0 6
Specific phobia 2 0 1
Total (n) 31 0 22
Data collected from only 26 patients where age relating to both fea-
tures was known. Ages at onset placed into following categories:
<18, 19–30, 31–30, 41–50 and >50 years. Simultaneous onset of
symptoms was considered when both sets of symptoms began in the
same age bracket. MC, manifesting carriers; DSM-IV, Diagnostic and
Statistical Manual of Mental Disorders, fourth edition.
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association between SGCE mutations and OCD,9 in par-
ticular the compulsivity component,7 while others have
reported no evidence of this in their cohort.5,8 Similar
results have been seen in mixed dystonia cohorts, some
finding an excess of OCD when compared to disability
matched and healthy controls23–25 while others have
found no evidence of an association.26 In M-D this may
represent a pleiotropic function of SGCE mutations for
the development of both motor and OC symptoms at an
age of increased vulnerability to these symptoms.
Anxiety-related disorders have been widely published in
previous M-D cohorts.8,13,27 However, GAD was the least
common psychopathology (17%) in this cohort, and
although significant, showed the smallest difference when
compared to both NMC and NC groups. This may be
explained by generalized anxiety and related disorders
(panic disorder, social and specific phobias) being ana-
lyzed separately in this study, rather than collectively as
has been done previously. Although focal dystonia and
anxiety-related symptoms have been postulated to share a
common pathophysiological pathway28 debate remains as
to whether this is a primary or secondary effect of the
movement disorder. Suggesting a primary mechanism,
several studies have reported onset of the anxiety symp-
toms prior to the movement disorder.29,30 However, both
studies involved mixed groups of focal dystonia, limiting
interpretation of the results. In our smaller cohort, near
equal numbers reported onset of their anxiety-related dis-
order either in conjunction with (11 cases) or subsequent
(10 cases) to development of their motor symptoms.
In this study, as with previous publications, we
attempted to determine whether SGCE mutations exerted
a gene independent effect in contributing to psychiatric
symptomatology, a finding that could have significant
implications to our understanding of underlying patho-
physiological mechanisms. No evidence of this was found
with exception of the lack of a statistically significant dif-
ference in the rate of MAD between MC and NMC
groups. However, there was no significant difference
between NMC and NC groups either and therefore this is
unlikely to represent an independent effect of SGCE
mutations. As with almost all previous studies7,15 our
attempts to identify a pleiotropic role for SGCE were lim-
ited by the small size of the NMC cohort. However, it is
also important to consider that manifestation of psychi-
atric symptoms, as is seen with the motor features, may
be similarly silenced due to the imprinting mechanism in
the presence of pathogenic mutations.
The use of different psychiatric assessments both
between and within individual centere represents a poten-
tial limitation of this study. Although all allow classifica-
tion of symptoms according to DSM-IV criteria, the
manner in which this is achieved differs between inter-
views. There is, however, evidence to suggest strong con-
cordance between SCID-I and MINI questionnaires,17
while the CIDI is designed for epidemiological studies
and demonstrates greater sensitivity. These interviews
were also administered by a number of different assessors
with differing training backgrounds. However, the stan-
dardized and systematic nature of all three questionnaires
limits the potential impact of personal bias and represents
the most pragmatic means of assessing a large population
across several countries. Finally, although much of the
standardized data collection referred to lifetime and pre-
sent diagnosis, age at onset for example was retrospec-
tively collected and therefore may be limited by recall
bias. A systematic prospective data collection in families
of affected probands, starting at an early age, remains the
only means to overcome this potential bias and given the
rarity of this disorder a multicenter international collabo-
ration would provide an opportunity to investigate this
further.
Conclusion
We have demonstrated a higher incidence of psychiatric
disorders in the motor affected SGCE mutation carriers
compared to nonmutation carrying familial controls in
the largest published cohort to date. Alcohol dependence,
OCD, social and specific phobias were the most strongly
associated disorders, consistent with the findings from
previous smaller studies. Although no gene independent
role for SGCE was demonstrated in this cohort, the con-
sistent finding of comorbid psychiatric disorders within
M-D cohorts suggests that in its active mutated form,
SGCE contributes to both motor and psychiatric symp-
toms. Further prospective work following affected pro-
bands and family members from an early age is required
to clarify the temporal pattern of onset of these symp-
toms, how they relate to one another, and what implica-
tions this may have on our understanding of the
pathogenesis of this disorder.
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